Nitrong

Quick links to important sections

Nitrong

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrong

Property Description
Active ingredient Nitroglycerin (Glyceryl Trinitrate, GTN)
Form Extended-release capsule, sublingual tablet, transdermal patch, spray, ointment
Pharmacological class Organic Nitrate, Vasodilator
General purpose Relieving strain and improving blood flow to the heart
Origin Synthetic compound

What is Nitroglycerin and its Role as an Organic Nitrate?

Nitrong is a prescription-only medication whose active ingredient is the chemical entity nitroglycerin, also formally known as glyceryl trinitrate (GTN). This synthetic compound belongs to the organic nitrate pharmacological class and is categorized primarily as a vasodilator. Its fundamental general purpose is to reduce the strain and oxygen demand placed upon the heart muscle, establishing its role as an anti-anginal agent. Nitrong manages vascular dynamics within the cardiovascular system, which effectively decreases the amount of effort the heart must exert to pump blood.

Composition and Differentiating Features of Nitrong

The composition of Nitrong centers on the single active substance, nitroglycerin, making it a single-ingredient product. A key differentiating feature for the Nitrong brand is its availability as an extended-release capsule format, designed to provide a sustained, long-acting effect, unlike the more rapidly absorbed sublingual forms. The drug is also formulated into diverse pharmaceutical preparations, including the sublingual tablet for rapid action and the transdermal patch (transdermal system). These forms utilize an inert base/vehicle appropriate for the specified route of administration, ensuring that the circulatory benefits of nitroglycerin are delivered according to the required onset and duration.

Regulatory References

  1. WHO Essential Medicine (Nitroglycerin) - IUPHAR/BPS Guide to PHARMACOLOGY
  2. Nitroglycerin Sublingual: MedlinePlus Drug Information (NIH)

What side effects are possible with Nitrong?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety restrictions for Nitrong, based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

The most commonly documented side effects are primarily related to the medicine's vasodilating effects. Regulatory documents classify these reactions by their incidence:

  • Very Common (Affecting 1 in 10 people or more): Headache.
  • Common (Affecting 1 to 10 in 100 people): Dizziness, lightheadedness, nausea, and flushing (redness of the face and neck).
  • Incidence Not Known (Reported in post-marketing experience): Syncope (fainting), paradoxical bradycardia (unusually slow heart rate), methemoglobinemia (a rare blood disorder), and marked hypotension (severe drop in blood pressure).

Serious and Clinically Significant Safety Concerns

Official documents note the potential for certain severe adverse events, including:

  • Severe Hypotension: Significant drops in blood pressure may occur, which can lead to cardiovascular collapse, particularly in individuals with pre-existing conditions.
  • Methemoglobinemia: A rare, life-threatening condition involving the blood's oxygen-carrying capacity.
  • Increased Intracranial Pressure: Use may be restricted in patients with conditions that already involve elevated pressure in the skull.

Safety Restrictions and Limitations

Nitrong is contraindicated (absolutely prohibited) for use in several situations due to a high risk of adverse events:

  • Drug Interactions: Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil) or riociguat is forbidden due to the risk of severe, life-threatening hypotension.
  • Underlying Conditions: It must not be used by patients with severe anemia, circulatory failure/shock, known hypersensitivity to organic nitrates, or certain heart conditions like constrictive pericarditis.

Population and Exposure Considerations

  • Pediatric Use: The safety and effectiveness of Nitrong have not been established in pediatric patients.
  • Elderly Patients: Caution is advised due to increased susceptibility to hypotensive effects and a greater risk of falls.
  • Exposure-Related Patterns: Tolerance (reduced effectiveness) may develop with excessive or continuous use. Furthermore, physical dependence has been documented in industrial settings with long-term, high-dose exposure, and abrupt cessation may result in withdrawal symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Nitrong (nitroglycerin) primarily leads to severe consequences from excessive vasodilation, as documented in regulatory information. Users or caregivers must be aware of the serious, officially documented manifestations and the required emergency actions.

Documented Overdose Manifestations

Symptoms reported in regulatory documents include profound hypotension (severely low blood pressure), persistent throbbing headache, flushing, dizziness (vertigo), visual disturbances, syncope (fainting), nausea, and vomiting. Severe overdose can lead to paradoxical bradycardia (slow heart rate) or reflex tachycardia.

Life-Threatening Complications

Uncorrected severe hypotension can lead to circulatory collapse. A specific and life-threatening complication documented in official labeling is methemoglobinemia, a condition where the blood's oxygen-carrying capacity is impaired. This may present as cyanosis (a bluish tint to the lips and skin), seizures, or coma, and requires specific medical intervention with an antidote.

Emergency Actions

The most important immediate action is to seek prompt medical attention or call emergency services immediately if overdose is suspected. Officially documented instructions for managing severe hypotension include placing the patient in a recumbent position and administering intravenous fluids to increase central blood volume. Treatment for methemoglobinemia is explicitly specified in the label as the administration of Methylene Blue. Continuous monitoring of vital signs and methemoglobin levels is required in a hospital setting.

Therapeutic Uses of Nitrong

What Nitrong Treats: Main Uses and Benefits

Nitrong is commonly used to help with the symptomatic relief of Angina Pectoris, which is relevant in conditions characterized by periods of heightened symptoms such as chest pressure, tightness, or squeezing pain. The medication is applied across therapeutic domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive and assists with addressing symptoms that create noticeable physiological strain.


Key Therapeutic Focus

Symptomatic management of Chronic Stable Angina is a primary area, alongside supportive relief for acute episodes of anginal discomfort. This medication is relevant for easing symptoms that interfere with daily comfort, particularly those related to physical discomfort triggered by exertion. This long-term use contributes to improved comfort during periods of heightened symptoms and generally assists with supporting functional stability, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Anginal Discomfort

Nitrong is applied across clinical settings that involve acute or disruptive symptom patterns, such as sudden onset of chest pressure or tightness. The core benefit may include symptomatic support during these episodes, helping to ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Nitrong?

Nitrong (Nitroglycerin) is officially approved for use in adults for the management of angina pectoris. Regulatory guidelines define eligibility based on absolute prohibitions and conditional requirements.

Absolute Non-Eligibility (Contraindications)

Nitrong must not be used by patients taking Phosphodiesterase-5 (PDE5) inhibitors (like sildenafil or tadalafil) or the soluble guanylate cyclase stimulator riociguat. The medicine is also strictly contraindicated for patients with severe anemia, increased intracranial pressure (including from head trauma), and specific obstructive heart diseases such as Hypertrophic Obstructive Cardiomyopathy.

Restricted and Conditional Use

For the pediatric population, safety and effectiveness have not been established, and use is officially not recommended. Additional caution is mandated for older adults and patients with severe hepatic or renal insufficiency. During pregnancy, use is restricted to cases where it is clearly needed, and caution is also advised during lactation.

What should I know about interactions with other medicines?

The regulatory documentation for Nitroglycerin (Nitrong) defines its interaction profile primarily through pharmacodynamic risk and specific modifications to co-administered drugs.

Contraindicated Combinations

Co-administration with Phosphodiesterase-5 (PDE-5) Inhibitors (such as sildenafil or tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (such as riociguat) is strictly contraindicated. This restriction is based on the potentiation of vasodilatory effects, which carries a documented risk of severe hypotension, syncope, or myocardial ischemia.

Pharmacodynamic and Exposure Interactions

Concomitant use with other antihypertensive agents (including calcium channel blockers and beta-adrenergic blockers) may produce officially documented additive hypotensive effects. Similarly, the consumption of alcohol (ethanol) is noted to cause or reinforce hypotension when co-administered due to shared vasodilatory properties.

A specific exposure interaction is documented with Ergotamine and related drugs; oral nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine, which increases its systemic exposure. The vasodilatory effects of Aspirin may be enhanced when co-administered. For intravenous use, Nitrong reduces the anticoagulant effect of Heparin and decreases the thrombolytic effect of Alteplase; regulatory documents require monitoring for these effects. The official profile does not list any specific CYP-enzyme or transporter-mediated interactions.

Mechanism of Action

How Nitrong Works

Nitrong's active ingredient, Glyceryl Trinitrate (GTN), operates through a mechanism focused entirely on modulating vascular tone by engaging the body's internal signaling systems. This action relies on a sequence of molecular steps that ultimately alters the hemodynamic load experienced by the heart.

Inside vascular cells, the enzyme Mitochondrial Aldehyde Dehydrogenase-2 (ALDH2) acts upon GTN, transforming it to release the active signaling molecule, Nitric Oxide (NO). This enzymatic activation is essential because the NO triggers the entire downstream physiological cascade.

Following its release, Nitric Oxide immediately activates the enzyme Soluble Guanylate Cyclase (sGC), dramatically increasing the second messenger cGMP. This increase promotes the relaxation of vascular smooth muscle by disrupting the cellular contractile apparatus, achieving widespread vasodilation throughout the circulatory system.

The resulting vasodilation significantly increases the capacity of the peripheral veins, causing blood to pool and reducing the volume of blood returning to the heart (lowering Preload). This effect, combined with the reduction in systemic vascular resistance (lowering Afterload), results in a decrease in the mechanical workload and associated oxygen demand of the cardiac muscle.

Dosage and Administration Information

How Nitrong is Used: Official Administration Guidelines

Nitrong (Nitroglycerin/Glyceryl Trinitrate) is administered via different routes, with specific procedural rules for each form.


Administration Routes and Dosing Regimens

Administration Route Standard Adult Dosing (Label-Based) Dosing Frequency/Pattern
Sublingual (Tablet/Spray) One dose (0.3 mg to 0.6 mg) at onset. As needed; may repeat every 5 minutes up to a maximum of 3 doses within 15 minutes.
Oral (Extended-Release Capsule) Typically 2.5 mg to 6.5 mg taken orally. Multiple times per day (e.g., 3 to 4 times a day) on a consistent schedule.
Topical (Transdermal Patch) Release rates from 0.1 mg/hr to 0.8 mg/hr applied to the skin. Cyclic use: 12 to 14 hours on, followed by a mandatory 10 to 12 hour drug-free interval daily.

Procedural Instructions and Constraints

Acute Use (Sublingual): The tablet must be placed under the tongue or in the cheek pouch and allowed to dissolve without being chewed, crushed, or swallowed. For administration, the patient should preferably be sitting down. For prophylactic use, the dose may be administered 5 to 10 minutes prior to engaging in activities likely to precipitate symptoms.

Chronic Use (Oral/Topical): The Extended-Release Capsule must be swallowed whole to maintain its sustained delivery mechanism. The Transdermal Patch requires application to a clean, dry, hairless skin site, and the site must be rotated daily. For all long-acting forms, the required 10 to 12 hour drug-free interval is essential to prevent pharmacological tolerance, which can compromise the medicine's effectiveness.

Population Rules: Dosing for older adults should be initiated cautiously, generally starting at the low end of the dosing range, reflecting the greater frequency of decreased organ function in this population.

Recent Clinical Evidence

Research evidence / Overview of studies for Nitrong


Evidence for Use in Managing Chronic Stable Angina

Research for long-acting nitroglycerin (GTN), the active ingredient in Nitrong, often focuses on short-term, placebo-controlled clinical trials. These studies were used in research exploring how symptoms change over time in adults with stable angina pectoris. Researchers primarily monitored outcomes reflecting daily functioning or activity level by using exercise stress tests. They also carefully monitored outcomes describing episodic or acute changes, such as the reported frequency of anginal episodes.

Initial findings in these short-term controlled settings described patterns where the measured time for activity level was observed to be different between groups receiving the long-acting GTN and those receiving placebo. Research highlights changes measured only during the study period, which were often just a few weeks in duration. A critical pattern that helps contextualize how patients reported their experience is related to nitrate tolerance. Research describes that the measured effect on functional outcomes was observed to become attenuated or diminish over time when the medication was administered on a continuous schedule in trials.


Long-Term Studies and Durability of Effect

Beyond the short-term trials, research has explored the drug's role in long-term observational settings evaluating daily-life functioning. The primary focus here was on the durability of the initial reported measurements related to the studied outcomes and tracking outcomes related to major health events. The available evidence for chronic, long-term use, especially concerning outcomes related to systemic or functional imbalance, is largely derived from these observational studies, rather than definitive, high-certainty long-term randomized trials. For this reason, long-term effects are not fully established.


Key Uncertainties and Research Gaps

One key limitation is the inherent challenge of nitrate tolerance, where measured changes may decrease over time, a pattern often observed when the medication is administered continuously. Research is ongoing to better understand this observed pattern. Furthermore, while short-term changes on outcomes reflecting daily functioning may be observed, there is limited information from definitive comparative evidence concerning major outcomes. The research provides context but not individual predictions, and the level of certainty for long-term systemic or functional imbalance outcomes is often described as low.

Key Studies & References

  1. NITROGLYCERIN EXTENDED-RELEASE CAPSULES - DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Nitrong (FAQ)


Q: Is Nitrong the same as other 'nitro' drugs, or is there a difference?

Nitroglycerin (Nitrong) is an organic nitrate. Official information describes it as a fast-acting nitrate primarily used as needed to help relieve chest pain.

In contrast, other similar nitrates, like isosorbide dinitrate, are often formulated as long-acting tablets taken on a consistent schedule with the purpose of preventing chest pain.


Q: How quickly can a person expect Nitrong to start working?

Studies on the sublingual (under-the-tongue) form of Nitrong indicate that the anti-anginal effect often begins rapidly, typically within 2 minutes of administration.


Q: How long do the effects of a dose of Nitrong usually last?

Clinical studies suggest that the full effects of a single sublingual dose of Nitrong are generally no longer measurable after approximately one hour post-administration.


Q: Can Nitrong be used to stop a heart attack, or is it just for pain?

The drug is officially approved for the management of angina (chest pain). The benefits of sublingual nitroglycerin in patients experiencing an acute myocardial infarction (heart attack) have not been established.

Official documents note that it may be considered in this setting.


Q: Can other common heart or blood pressure medications be taken with Nitrong?

Regulatory documents indicate that taking Nitrong with other medications used for high blood pressure is officially documented to produce additive hypotensive effects (a combined drop in blood pressure).

Consultation with a healthcare provider regarding the full medication list is important given the potential for additive effects.


Q: Why is it advised to sit down before using the sublingual form of Nitrong?

Official patient information advises patients to sit down when taking the sublingual tablets or spray. This is recommended to reduce the possibility of falling or injury if temporary effects like lightheadedness or dizziness occur due to the medicine's effect of lowering blood pressure.


Q: Is it safe to drink alcohol while taking Nitrong?

Concomitant use with alcohol is documented in regulatory sources to cause or reinforce hypotension (low blood pressure).

This interaction is associated with a possible increase in side effects such as dizziness, lightheadedness, or fainting.


Q: What is known about the use of Nitrong during pregnancy or while breastfeeding?

For pregnancy, official documents state that use should occur only if the potential benefit justifies the potential risk to the fetus. For breastfeeding, there are no adequate studies in women, and caution is officially advised.


Q: What is nitrate tolerance, and why is it a concern with Nitrong?

Nitrate tolerance is the development of a diminished response or effect from the drug when it is taken continuously or too frequently. It is a known concern because it can reduce the anti-anginal effect and overall effectiveness of the medicine over time.


Q: Why is a 'drug-free' interval often suggested for certain forms of Nitrong?

The drug-free interval (a period of time without the medication, such as when using a patch) is necessary to prevent nitrate tolerance from developing.

Clinical trials have shown that the effectiveness of continuously delivered nitrates diminishes over time, and this interval helps to maintain the drug's therapeutic benefit.


Q: Can Nitrong lose its effectiveness over time or if stored incorrectly?

Regulatory-based advice states that the sublingual tablets, in particular, are a volatile substance and can lose potency if not kept in the original, tightly closed glass container.

Storing the product incorrectly may result in the medicine not retaining its expected potency when needed.


Q: Does Nitrong help with high blood pressure in general?

While oral forms of the medicine are primarily indicated for angina, nitroglycerin is a potent vasodilator (widens blood vessels) and is capable of lowering blood pressure.

The intravenous form is officially indicated for the control of blood pressure in certain surgical settings.


Q: Can the feeling of lightheadedness be managed while using Nitrong?

Official patient information describes that getting up slowly from a sitting or lying position may help minimize lightheadedness or dizziness.

Lying down for a short while may also help relieve these specific feelings.


Q: Are there any specific activities or environments, like hot weather, that increase the side effects of Nitrong?

Official patient information notes that side effects such as dizziness, lightheadedness, or fainting are more likely to occur if a person is standing for long periods, engaging in exercise, or when the weather is hot.


Q: What should a patient do if they accidentally swallow the sublingual tablet or spray?

The sublingual forms are designed for rapid absorption through the lining of the mouth, not the stomach.

Official patient resources indicate that the proper effect may not be achieved, as the medicine is not intended for absorption via the digestive system.


Q: Can using Nitrong make symptoms of an existing condition, like glaucoma, worse?

While not an absolute contraindication, regulatory-based information lists glaucoma (a condition involving pressure in the eye) as a condition that requires careful use of the drug due to the potential for an increase in internal eye pressure.


Q: Is it possible to have an allergic reaction to the adhesive in the Nitrong patch?

Adverse reaction reports for the transdermal patch include incidents of itching, scaling, or severe redness of the skin, and hives or rash.

These skin-related side effects may be associated with the materials in the patch.


Q: Can Nitrong cause a fast or irregular heartbeat?

Yes, official documents list palpitation (the sensation of a fast or fluttering heartbeat) and rapid heart rate as potential, though less common, adverse reactions.


Q: Can using Nitrong cause dry mouth?

Yes, dry mouth is listed in regulatory documents as an adverse reaction, sometimes occurring as a rare side effect.

It is noted as one of the reactions that has been associated with the discontinuation of the drug.


Q: Can Nitrong affect my vision or cause blurred eyesight?

Yes, regulatory documents list blurred vision as a potential adverse reaction. Blurring of vision is listed as an adverse reaction that, according to official information, warrants consideration for discontinuation.


Q: Can certain forms of Nitrong, like the patch, cause skin irritation?

Reports for the transdermal patch list skin reactions such as blistering, burning, crusting, dryness, or flaking at the application site.

These effects are noted to have an incidence that is not known.


Q: Is there any research on Nitrong's use in chronic heart failure?

While the primary approved use is for angina, official-based information notes that research has explored vasodilators, including isosorbide dinitrate (a related nitrate), for use in chronic heart failure.


Q: Why is it important to tell a dentist that I am using Nitrong?

Regulatory patient information advises individuals to inform their dentist or surgeon that they are using the medicine.

This is due to the potential need for temporary adjustment of the medicine before certain medical procedures or tests.


Q: What are the signs of taking too much Nitrong?

Symptoms of overdose are documented to include a severe, pounding headache, significant low blood pressure, changes in heart rate (which can be rapid or slow), confusion, and fainting.


Q: Does physical activity or exercise influence how Nitrong works?

Yes, the sublingual form can be taken prophylactically (in advance) before engaging in activities like exercise that are known to precipitate chest pain.

Side effects like dizziness or lightheadedness are also noted to be more likely during exercise.

How should Nitrong be stored and disposed of?

How to Store and Dispose of Nitroglycerin (Nitrong)

Official regulatory documents define strict requirements for storing and disposing of nitroglycerin products to maintain potency and ensure safety.


Storage and Potency Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C). Do not freeze.
Protection Protect from light, excess heat, and moisture.
Container Rule Sublingual tablets must be kept in their original, tightly closed glass container.
Stability Discard sublingual tablets six months after the bottle is first opened.
Safety Keep all forms of the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired product should be disposed of according to the guidance provided by a healthcare professional or local regulations. Used transdermal patches must be folded in half with the sticky sides together before disposal to prevent unintended exposure, especially to children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitrong found in:

A-Z Index: